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Abstract
The C and V proteins of the measles virus (MV) have been shown to block the signaling of type I and II interferon (IFN-α/β and IFN-γ). The
relative contribution of the C and V proteins to the inhibition of IFN signaling and the extent to which this activity differs in attenuated or wild-type
strains of MVremains undefined. This study presents a comparison of the IFN-antagonist activities of C and V proteins from four attenuated and two
wild-type strains ofMV. TheV proteins were more potent inhibitors of IFN-inducible reporter gene expression than the C proteins, and this effect was
unrelated to whether the protein originated from an attenuated or wild-type strain. The results also demonstrated the importance of the tyrosine at
position 110 in the inhibition of IFN-α/β and IFN-γ signaling by the V protein, and identified a non-recombinant MVexpressing a V protein that was
impaired due to a mutation at this residue.
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Measles virus (MV) infection is a major cause of childhood
morbidity and mortality, accounting for approximately 345,000
deaths annually (Wolfson et al., 2007). Due to the widespread use
of live attenuated vaccines for measles, this disease has been
eliminated in the Western Hemisphere since 2000. Additionally,
the European, Eastern Mediterranean andWestern Pacific regions
of the World Health Organization have set elimination goals for
the near future (CDC, 2005). Despite these successes, measles
remains endemic inmany developing countries, especially in Sub-
Saharan Africa and Asia, due to inadequate vaccine coverage.
MV is a member of the genus Morbillivirus of the family
Paramyxoviridae. The genome of MV is 15,894 nucleotides in
length and consists of six tandemly linked genes that encode, from☆ Disclaimer: The findings and conclusions in this report are those of the
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doi:10.1016/j.virol.2007.12.0313′ to 5′, the nucleocapsid (N), phosphoprotein (P), matrix (M),
fusion (F), hemagglutinin (H), and large (L) proteins (Griffin,
2001). In addition to coding for the P protein, an essential cofactor
of the viral polymerase, the P gene of MVencodes two accessory
proteins, C and V. The C protein is a small (186 amino acids),
basic protein that is synthesized from a translation start signal on
the P mRNA that is 22 nucleotides downstream from the P start
site (Bellini et al., 1985). The C protein functions to downregulate
viral polymerase activity (Bankamp et al., 2005; Reutter et al.,
2001), enhance the production of infectious viral particles (De-
vaux and Cattaneo, 2004), and maintain long-term MV infection
by preventing cell death (Takeuchi et al., 2005). In contrast, the V
protein is translated from the same start codon as the P protein, but
a co-transcriptionally inserted guanosine at the RNA editing site
causes a frame shift. The resulting V protein shares its first 231
amino acids with the P protein, but has a unique 68 amino acid
carboxy-terminal domain that includes seven conserved cysteine
residues (Cattaneo et al., 1989; Liston andBriedis, 1994;Wardrop
and Briedis, 1991). The V protein is known to downregulate viral
polymerase activity (Tober et al., 1998) and inhibit apoptosis
through interaction with the tumor suppressor p73 protein (Cruz
Table 1
Differences in sensitivity of attenuated and wild-type MV titers to the presence
of IFN a
Virus Titer (p.f.u./mL) Fold decrease of viral titer
in presence of IFN
No IFN IFN-β IFN-γ
EdTag 5.38×106 3093.94 53.14
Moraten 2.98×105 89.11 96.46
CAM-70 1.36×105 6.20 4.84
EZ 1.89×106 25.78 5.29
Indiana 1.98×105 23.42 2.65
D87-V/S 2.63×105 1.89 1.94
EMC 6.50×104 3300.00 800.00
a This table was derived from an average of three experiments done in triplicate.
72 J.M. Fontana et al. / Virology 374 (2008) 71–81et al., 2006). Both the C and V proteins of MV contribute to viral
evasion of the host interferon (IFN) response (Andrejeva et al.,
2004; Childs et al., 2007; Devaux et al., 2007; Nakatsu et al.,
2006; Ohno et al., 2004; Palosaari et al., 2003; Shaffer et al., 2003;
Takeuchi et al., 2003).
Type I IFN (IFN-α/β) and type II IFN (IFN-γ) are potent
inflammatory cytokines that are induced in direct response to viral
infection and have important roles in the inhibition of viral repli-
cation and the regulation of host immunity (Goodbourn et al.,
2000; Stark et al., 1998). Both IFN-α/β and IFN-γ signal through
similar, yet distinct Janus kinase-signal transducer and activator of
transcription (JAK-STAT) signal transduction pathways by bin-
ding to their cognate receptors on the surface of cells. This
receptor-ligand interaction and signaling pathway results in the
upregulation of IFN-stimulated gene (ISG) products that con-
tribute to host immune regulation and the establishment of an
antiviral state (Goodbourn et al., 2000; Stark et al., 1998).
The accessory proteins encoded by the P gene of many para-
myxoviruses have the ability to interfere with the IFN signaling
pathway. For example, the C proteins of Sendai virus (Garcin
et al., 1999; Gotoh et al., 1999) human parainfluenza virus 3
(Malur et al., 2005), Nipah virus (Park et al., 2003), rinderpest
virus (Nanda and Baron, 2006), and measles virus (Shaffer et al.,
2003) block IFN signaling. Likewise, the V proteins of simian
virus 5 (Didcock et al., 1999; Poole et al., 2002), simian virus 41
(Nishio et al., 2001), mumps virus (Kubota et al., 2001), human
parainfluenza virus 2 (Nishio et al., 2001; Parisien et al., 2001),
Nipah and Hendra viruses (Park et al., 2003; Rodriguez et al.,
2002; Rodriguez et al., 2003), Newcastle disease virus (Huang
et al., 2003), rinderpest virus (Nanda and Baron, 2006), and
measles virus (Palosaari et al., 2003; Takeuchi et al., 2003) also
block IFN signaling. Recently, a role in the inhibition of IFN
signaling was demonstrated for the P proteins of Nipah virus
(Shaw et al., 2004), rinderpest virus (Nanda and Baron, 2006),
and measles virus (Devaux et al., 2007). Additionally, the acces-
sory proteins of many paramyxoviruses inhibit the IFN induction
pathway (Andrejeva et al., 2004; Childs et al., 2007; He et al.,
2002; Kiyotani et al., 2007; Komatsu et al., 2007; Nakatsu et al.,
2006; Poole et al., 2002; Strahle et al., 2007).
Although both the C andV proteins ofMVhave been shown to
inhibit IFN signaling, there are inconsistencies in the results
reported from different laboratories (Ohno et al., 2004; Palosaari
et al., 2003; Shaffer et al., 2003; Takeuchi et al., 2003). Whereas
Shaffer et al. (2003) demonstrated the inhibition of an IFN-α/β-
responsive reporter gene by the C protein, other studies reported
weak or no inhibition (Ohno et al., 2004; Takeuchi et al., 2003,
2005). There is agreement that the V protein inhibits IFN-α/β
signaling (Devaux et al., 2007; Ohno et al., 2004; Palosaari et al.,
2003; Takeuchi et al., 2003), but there are conflicting reports
about the suppression of IFN-γ signaling by this protein (Palo-
saari et al., 2003; Takeuchi et al., 2003). Some of these dis-
crepancies may be due to the use of different viral strains and cell
types.
Since it is possible that the IFN-inhibitory functions of the C
and V proteins of MVmay depend on the strain from which they
are derived, the relative abilities of the C and V proteins of four
attenuated and two wild-type strains of MV to inhibit IFN-α/βand IFN-γ signaling in the absence of IFN induction were
compared in this study. In all strains tested, the V protein of MV
inhibited IFN signaling with greater efficiency than its corres-
ponding C protein, an effect that was independent of whether the
protein was derived from a wild-type or attenuated virus. Addi-
tionally, the V proteins from the EdTag and CAM-70 strains
were impaired in their ability to inhibit both IFN-α/β and IFN-γ
signaling due to a substitution at amino acid 110. Restoration of
the tyrosine at this position recovered the IFN-antagonistic fun-
ction of both proteins.
Results
Sensitivity of attenuated and wild-type MV titers to the
presence of IFN
Six isolates of MV were chosen for analysis in this study,
including three vaccine strains (CAM-70, Moraten, and Edmon-
ston–Zagreb (EZ)), a recombinant virus derived from a labo-
ratory strain of Edmonston (EdTag), and two wild-type strains
(Indiana and D87-V/S). To investigate the sensitivity of these
strains to IFN, we infected cells, treated them with IFN or left
them untreated, and measured the resulting viral titers. Vero/
hSLAM cells, which cannot produce IFN (Emeny and Morgan,
1979), were used to rule out the effects of IFN induction by MV
infection. All MV strains grew to comparable titers in the
absence of IFN (Table 1). EdTag was extremely sensitive to the
presence of IFN-β. Moraten, EZ, and Indiana were intermedi-
ately sensitive to IFN-β, with Moraten exhibiting approxi-
mately 60-fold higher sensitivity than EZ or Indiana. CAM-70
and D87-V/S were minimally sensitive to IFN-β (Table 1).
Interestingly, the two wild-type strains exhibited statistically
different levels of sensitivity to IFN-β ( pb0.05). Regarding
sensitivity to the presence of IFN-γ, Moraten and EdTag were
both intermediately sensitive, while the other strains were only
minimally sensitive (Table 1). These data do not reveal any
distinction between wild-type and attenuated strains of MV
based on their ability to replicate in the presence of an IFN-
induced antiviral state. Encephalomyocarditis (EMC) virus was
used as a control in this study since its replication is extremely
sensitive to the presence of IFN (Green et al., 1980). As
Fig. 1. Expression of theC proteins (panel A) andVproteins (panel B) ofMV.Vero
cells were transfected with the indicated C or V protein-expressing plasmid or an
empty vector (pCAGGS). Proteins were 35S-methionine labeled, immunoprecipi-
tated with peptide-specific antiserum, and separated by SDS-polyacrylamide gel
electrophoresis. The positions of the C and V proteins are indicated on the right
(arrows), and the molecular weight marker is indicated on the left.
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exposure to both IFN-β and IFN-γ (Table 1).
Transient expression of C and V proteins
The C or Vopen reading frame (ORF) of each MV strain was
cloned into the mammalian expression vector, pCAGGS, which
permits high levels of protein expression from a ubiquitously
strong promoter (Niwa et al., 1991). The C ORF was silenced in
the V constructs without altering the V amino acid sequence.
The nucleotide sequences of the P genes for EdTag, Moraten,
CAM-70, EZ, Indiana, and D87-V/S were confirmed by com-
parison to the published sequences (Table 2).
All six C plasmids expressed proteins of approximately 20 kDa
that reactedwith antiserum to the C protein ofMV (Fig. 1). All six
V plasmids expressed proteins that reacted with antiserum to the
shared region of the P and V proteins of MV (Fig. 1). The proteinsTable 2
Amino acid variability among V proteins used in this study
aStrain names are abbreviated as Edwt (Edmonston wild-type), ET (EdTag), Mor
(Moraten), CAM (CAM-70), EZ (Edmonston–Zagreb), Ind (Indiana), V/S (D87-
V/S). The GenBank accession numbers for the P gene sequences were: Edwt
(AF266288), ET (Z66517), Mor (UO1984), CAM (DQ435723), EZ
(AF266290), Ind (EU026136).
bSingle-letter amino acid code.
cThe amino acids found by Ohno et al. (2004) to control IFN-α/β-antagonism in
the V protein are indicated by shading.expressed by five of these plasmids were approximately 34 kDa,
and the protein expressed by the CAM-70 V plasmid was appro-
ximately 36 kDa. The C and V proteins expressed from plasmid
DNA co-migrated with the C and V proteins immunoprecipitated
from Vero/hSLAM cells infected with the same strain (data not
shown). The predicted molecular weights of the V proteins are
similar despite amino acid differences. Therefore, the slower
migration of the CAM-70 V protein could be caused by diffe-
rences in post-translational modifications, such as phosphoryla-
tion. The P and V proteins of MV can be phosphorylated on
tyrosine, serine, and threonine residues, but an effect on protein
function has not yet been demonstrated (Das et al., 1995; Liu et al.,
1997; Ofir et al., 1996).
Effect of C and V proteins from wild-type and attenuated
strains of MV on IFN-α/β signaling
The relative abilities of the C and V proteins of MV to inhibit
IFN-α/β signaling were determined by measuring the effect of
different doses of each protein on the expression of an IFN-α/β-
responsive reporter gene. Transfection of increasing amounts of
plasmids expressing the C proteins resulted in marginal inhibition
of firefly luciferase production. The level of inhibition of reporter
gene expression with 0.5 μg of plasmid expressing the C proteins
of CAM-70, Moraten, and Indiana was 16.4%, 15.5%, and
13.0%, respectively. The inhibition increased slightly to 28.6%,
24.9%, and 25.5%, respectively, with the addition of 1 μg of C
protein-expressing plasmid, but it remained approximately the
same with plasmid concentrations up to 2 μg (Fig. 2A). In
contrast, the V protein of MV inhibited IFN-α/β-responsive
reporter gene expression in a dose-dependent manner, reaching
levels of 82–90% with the addition of 1 μg of V protein-express-
ing plasmid (Fig. 2B). These data suggest that theV protein ofMV
is a more potent inhibitor of IFN-α/β signaling than the C protein.
To determine whether the ability of the C and V proteins of
MV to inhibit IFN-α/β signaling correlated with the derivation of
that protein from an attenuated or wild-type virus, C and V
proteins of different strains were compared in their ability to
inhibit IFN-α/β-responsive reporter gene expression. The EZ and
D87-V/S C proteins inhibited reporter gene expression by 10.1%
and 29.9%, respectively (pb0.05), while the EdTag, Moraten,
CAM-70, and Indiana C proteins did not inhibit (Fig. 2C). In
Fig. 2. The C and V proteins of MV inhibit IFN-α/β-responsive reporter gene expression. Vero cells were transfected with a plasmid constitutively expressing renilla
luciferase and a plasmid expressing firefly luciferase under the control of an IFN-α/β-responsive promoter. The cells were also transfected with plasmids expressing
(A) C proteins or (B) V proteins from CAM-70, Moraten, or Indiana strains of MV at varying doses, or with 1.0 μg of plasmid expressing (C) C proteins or (D) V
proteins from each of six strains of MV. 48 h post-transfection, the cells were stimulated with 100 U IFN-β for 6 h, lysed, and tested for luciferase activity. Stimulated
pCAGGS constituted a negative control for inhibition of IFN-responsive gene expression (VC+), and unstimulated pCAGGS was used to show background levels of
firefly luciferase luminescence (VC−). A plasmid expressing the Sendai virus C proteins was used as a positive control for inhibition of IFN-responsive gene
expression. Results are expressed as a ratio of firefly to renilla luciferase luminescence taken as a percentage of the luminescence obtained using IFN-stimulated, empty
pCAGGS vector. The data shown are an average of six experiments done in triplicate. Statistics were performed using Student's t-test.
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EdTag and CAM-70 V proteins, inhibited reporter gene expres-
sion at levels between 88.5% and 89.4%. The EdTag V protein
poorly inhibited reporter gene expression (6.3%) and this result
was consistent with a previous report (Ohno et al., 2004). The V
protein from CAM-70 was also not as potent an inhibitor as the
other V proteins (71.5%) (Fig. 2D). These results provide further
evidence that the V proteins of MVare more potent inhibitors of
IFN-α/β signaling than the C proteins. There was no indication
that C or V proteins that displayed greater inhibition of IFN-α/β
signaling were from either attenuated or wild-type strains of
MV. Additionally, the inability of the EdTag V protein to inhibit
IFN-α/β signaling was confirmed in these experiments, and an
additional V protein was found to be impaired in this function.
Since it has been suggested that the C and V proteins of MV
might exist in a complex with components of the IFN-α/β
receptor (Yokota et al., 2003), we investigated the effect of co-
expressing the C and V proteins. The V protein was expressed at alevel that inhibited reporter gene expression by approximately
40–80%, and an increasing amount of plasmids expressing C
proteins from the corresponding strain of MV was added. The
CAM-70 and Moraten C proteins did not increase the level of
inhibition observed with the V protein of these strains alone
(Fig. 3A). However, the EZ andD87-V/S C proteins increased the
level of inhibition when co-expressed with the V protein of the
same strain (Fig. 3B). Taken together, these data suggest that
while the C protein of MV has a weak inhibitory effect on IFN-α/
β signaling, the V protein of MV is a stronger inhibitor of IFN-α/
β signaling. Furthermore, the C and V proteins of some strains of
MV may act in an additive manner to inhibit IFN-α/β signaling.
Effect of C and V proteins from wild-type and attenuated
strains of MV on IFN-γ signaling
While there is some evidence to suggest that the C protein of
MV can inhibit IFN-γ signaling (Shaffer et al., 2003), the
Fig. 3. The C and V proteins of some strains of MVmay act in an additive manner
to inhibit IFN-α/β-responsive reporter gene expression. Vero cells were transfected
with a plasmid constitutively expressing renilla luciferase and a plasmid expressing
firefly luciferase under the control of an IFN-α/β-responsive promoter. The cells
were also transfected with plasmids expressing the V protein from (A) CAM-70 or
Moraten or (B) EZ or D87-V/S strains of MV at doses which inhibited IFN-α/β
signaling by 40–80% and varying doses of plasmids expressing the C protein from
the same virus. 48 h post-transfection, the cells were stimulated with 100 U IFN-β
for 6 h, lysed, and tested for luciferase activity. Results are expressed as a ratio of
firefly to renilla luciferase luminescence taken as a percentage of the luminescence
obtained using IFN-stimulated, empty pCAGGS vector. As described in the legend
to Fig. 2, stimulated (VC+) and unstimulated (VC−) pCAGGS were used as
negative controls, and a plasmid expressing the Sendai virus C proteinswas used as
a positive control. The data shown are an average of three experiments done in
triplicate. Statistics were performed using Student's t-test.
Fig. 4. The V proteins of MV inhibit IFN-γ-responsive reporter gene expression.
Vero cells were transfected with a plasmid constitutively expressing renilla
luciferase and a plasmid expressing firefly luciferase under the control of an IFN-γ-
responsive promoter. The cells were also transfected (A) with plasmids expressing
V proteins from CAM-70, Moraten, or Indiana strains of MVat varying doses, or
(B) with 1.0 μg of plasmid expressing V proteins from each of six strains of MV.
48 h post-transfection, the cells were stimulated with 1000 U IFN-γ for 6 h, lysed,
and tested for luciferase activity. Results are expressed as a ratio of firefly to renilla
luciferase luminescence taken as a percentage of the luminescence obtained using
IFN-stimulated, empty pCAGGS vector. As described in the legend to Fig. 2,
stimulated (VC+) and unstimulated (VC−) pCAGGS were used as negative
controls, and a plasmid expressing the Sendai virus C proteins was used as a
positive control. The data shown are an average of six experiments done in
triplicate. Statistics were performed using Student's t-test.
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et al., 2003; Takeuchi et al., 2003). The relative abilities of the C
and V proteins of MV to inhibit IFN-γ signaling were deter-
mined by measuring the effect of different doses of each protein
on the expression of an IFN-γ-responsive reporter gene. Addi-
tion of increasing concentrations of plasmids expressing the C
protein to this system did not inhibit IFN-γ-responsive reporter
gene expression (data not shown). In contrast, the V proteins of
CAM-70, Moraten, and Indiana inhibited IFN-γ-responsive
reporter gene expression in a dose-dependent manner, reaching
maximum inhibition levels of 36.0%, 83.0%, and 81.6%,
respectively (Fig. 4A). These data indicate that the V protein is a
potent inhibitor of IFN-γ signaling, while the C protein does not
inhibit at all.
To test whether the ability of the C and V proteins to inhibit
IFN-γ signaling was dependent on the strain of MV from which
it was derived, C and V proteins from attenuated and wild-type
strains of MV were tested for inhibition of IFN-γ-responsive
reporter gene expression. None of the C proteins were able to
inhibit IFN-γ-responsive reporter gene expression (data notshown). In contrast, the V proteins exhibited marked inhibition
of IFN-γ-responsive reporter gene expression, with the excep-
tion of the V proteins from EdTag and CAM-70, which did not
inhibit to the same extent as the other V proteins (11.0% and
24.5%, respectively) (Fig. 4B). These results show that the V
proteins of MV are more potent inhibitors of IFN-γ signaling
than the C proteins, which do not inhibit. As shown above for
IFN-α/β, there was no correlation between the potency of
inhibition of IFN-γ signaling by a C or V protein and its derivation
from an attenuated or wild-type strain. Furthermore, both the
EdTag and CAM-70 V proteins were impaired in their ability to
inhibit IFN-γ signaling.
Fig. 5. Tyrosine 110 is important for the IFN­antagonistic activity of the V
protein. (A) The CAM­70 and EdTag V proteins and their mutants were 35S­
methionine labeled and detected by immunoprecipitation with rabbit antiserum
specific to the shared amino­terminus of the P and V proteins and SDS­PAGE
analysis, as described in Figure 1. As described in Figures 2 and 4, luciferase
activity was determined in Vero cells that were transfected with plasmids encoding
renilla luciferase, firefly luciferase under the control of (B) an IFN­α/β­responsive
promoter or (C) an IFN­γ­responsive promoter, and the indicated protein. Results
are expressed as a ratio of firefly to renilla luciferase luminescence taken as a
percentage of the luminescence obtained using IFN­stimulated, empty pCAGGS
vector. As described in the legend to Figure 2, stimulated (VC+) and unstimulated
(VC­) pCAGGS were used as negative controls, and a plasmid expressing the
Sendai virus C proteins was used as a positive control. The data shown are an
average of three experiments done in triplicate. Statistics were performed using
Student's t-test.
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protein from the CAM-70 strain of MV
As previously reported, the EdTag V protein differs from the
Edmonston V protein at amino acid positions 110 (tyrosine to
histidine), 272 (cysteine to arginine), and 291 (tyrosine to his-
tidine), with the substitutions at positions 110 and 272 shown to
be important for the inhibition of IFN-α/β-responsive reporter
gene expression (Ohno et al., 2004). The EdTag V protein used
in the present study contained the three mutations described
above and an additional amino acid substitution at position 225
(glutamic acid to glycine) (Table 2), which was reported to be
conserved in vaccine strains of MV (Parks et al., 2001). The
CAM-70 V protein contained 10 amino acid differences com-
pared to the Edmonston V protein, including a tyrosine to
cysteine change at amino acid position 110 (Table 2).
To explore the role that amino acid 110 in the V protein of
MV plays in inhibition of IFN signaling, the plasmids expressing
the V protein of EdTag or CAM-70 were modified to change the
histidine or cysteine at position 110 to tyrosine. Expression of
these mutant proteins, referred to as CAM-70 V(C110Y) and
EdTag V(H110Y), was confirmed by immunoprecipitation with
antiserum to the shared region of the P and V proteins of MVand
SDS-PAGE analysis (Fig. 5A). The modified V proteins were
compared with the unmodified V proteins in their ability to
inhibit the expression of an IFN-α/β- or IFN-γ-responsive
reporter gene. Both CAM-70 V(C110Y) and EdTag V(H110Y)
displayed significantly increased inhibition of both IFN-α/β and
IFN-γ signaling. As expected, the mutation in the EdTag V
protein did not fully restore its ability to inhibit IFN-α/β-res-
ponsive reporter gene expression (Ohno et al., 2004) (Fig. 5B).
However, the mutation in the CAM-70 V protein was sufficient
to bring its IFN-α/β-antagonistic activity to the level observed
for the other V proteins tested (Fig. 5B). The introduction of a
tyrosine at amino acid residue 110 was sufficient to restore the
ability of both proteins to inhibit IFN-γ-responsive reporter gene
expression (Fig. 5C). These data indicate that amino acid 110
plays a role in the ability of the V protein of MV to inhibit both
IFN-α/β and IFN-γ signaling.
Discussion
Although the C and V proteins of MV have been previously
implicated as inhibitors of IFN signaling, the relative contribution
of each protein to this activity was unclear. This report
demonstrated that the C protein marginally blocked the expres-
sion of an IFN-α/β-responsive reporter gene, but was unable to
block IFN-γ-responsive reporter gene expression. In contrast, the
V protein blocked the expression of IFN-α/β- and IFN-γ-
responsive reporter genes. The level of IFN-inhibition was unre-
lated to whether the protein was derived from an attenuated or
wild-type strain of MV. We confirmed the importance of a
tyrosine at amino acid 110 for the IFN-α/β-antagonist function of
the V protein, and demonstrated a role for this residue in the
inhibition of IFN-γ signaling. Notably, this report is the first to
identify a non-recombinant MV that produced a V protein that
was impaired due to a mutation at this residue.
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Edmonstonwild-type strain ofMVinhibited the expression of an
IFN-α/β-responsive reporter gene and, to a lesser extent, an
IFN-γ-responsive reporter gene in Vero cells (Shaffer et al.,
2003). The data presented here correspond with subsequent
studies performed in other cell types suggesting that C has a
minor role in the inhibition of IFN signaling (Nakatsu et al.,
2006; Ohno et al., 2004; Takeuchi et al., 2005). Discrepancies
between the data in this report and our previous results were
probably due to improvements in the IFN-responsive reporter
gene assay, including the use of a more sensitive detection
method, an expression vector which produced lower back-
ground, and the inclusion of more biologically relevant strains of
MV. Additionally, since the MV that lacked the C protein in the
study by Shaffer et al. (2003) also expressed impaired V and P
proteins, the contribution of the C protein to the inhibition of IFN
signaling may have been overestimated. A recent study sug-
gested that the C protein of MV blocks IFN induction (Nakatsu
et al., 2006), and there is evidence that the C proteins of other
paramyxoviruses may also have this ability (Strahle et al., 2007;
Van Cleve et al., 2006). It is therefore possible that, while the C
protein may have a minor role in the inhibition of IFN-α/β
signaling, it is more important in limiting IFN induction.
Although it is widely recognized that the V protein of MV
inhibits IFN-α/β signaling, the impact of this protein on IFN-γ
signaling is a subject of debate in the literature. This study and a
study by Palosaari et al. (2003) both support the conclusion that
the V protein inhibits IFN-α/β and IFN-γ signaling. In contrast,
Takeuchi et al. (2003) reported that the V protein could not
inhibit IFN-γ signaling. A major difference between these
studies was that Takeuchi et al. (2003) used a HeLa cell line that
stably expressed the V protein of MV, while the other studies
relied on transient expression of the V protein, a method that
may more accurately reflect the de novo synthesis and accu-
mulation of the V protein that occurs during MV infection.
All V proteins tested in this study were more potent inhi-
bitors of IFN-α/β and IFN-γ signaling than were the corres-
ponding C proteins from each strain. This result suggests that
the V protein might be the major inhibitor of IFN signaling
during MV infection. Devaux et al. (2007) recently found that
while the P protein of MV inhibited the IFN-α/β response, the
level of inhibition was 10-15 fold less than that observed for the
V protein. In rinderpest virus, a closely related paramyxovirus
in the genus Morbillivirus, the V protein was the dominant
inhibitor of IFN compared to the P and C proteins of that virus
(Nanda and Baron, 2006). Additionally, the P protein of Nipah
virus, a member of the genus Henipavirus, exhibited weaker
IFN-antagonistic activity than the VandW proteins of that virus
(Shaw et al., 2004). Further studies that directly compare the C,
V, and P proteins of MV will be needed to strengthen the
argument that the V protein is the primary inhibitor of IFN
signaling during infection with MV.
This is the first report to investigate the effect of co-expres-
sing the C and V proteins of MVon IFN-α/β signaling. The two
C proteins (EZ and D87-V/S) that improved the inhibition of an
IFN-α/β-responsive reporter gene when co-expressed with their
corresponding V protein were also the two C proteins thatinhibited IFN-α/β signaling in the absence of V. Of course, the
inability to detect significant inhibition with the C proteins from
other strains of MV could be a function of the sensitivity of the
reporter gene assay. Future studies will be needed to determine
the mechanism of the additive effect of the C and V proteins on
the inhibition of IFN signaling.
In this study, the IFN-antagonist activity of the V protein was
unrelated to whether the protein was derived from an attenuated
or wild-type strain of MV, but it correlated with the presence of
a tyrosine at amino acid 110. Three previous studies have noted
the importance of this residue in the shared region of the P and
V proteins of MV (Caignard et al., 2007; Devaux et al., 2007;
Ohno et al., 2004). This is the first report of a cysteine sub-
stitution at amino acid 110 in the V protein of a non-recom-
binant strain of MV that resulted in impaired IFN-antagonism.
Additionally, this is the first report that demonstrated the
importance of this residue for the inhibition of IFN-γ signaling
by the V protein. Interestingly, changing amino acid 110 to a
tyrosine in the EdTag V protein improved, but did not fully
restore its ability to inhibit IFN-α/β signaling. This observation
was also reported by Ohno et al. (2004), who pointed out that a
cysteine to arginine change at position 272 in the unique car-
boxy-terminal region was also important. Caignard et al. (2007)
demonstrated that the amino- and carboxy-terminal domains of
the V protein could individually inhibit IFN-α/β signaling. This
indicates that both regions of the V protein may be needed to
inhibit IFN-α/β signaling. Further studies are needed to fully
map the regions involved in the inhibition of IFN signaling by
the V protein.
The involvement of amino acid 110 in the inhibition of both
IFN-α/β and IFN-γ signaling indicates that it may be important
for the interplay of the V protein with common components of
these pathways, such as STAT1 or Jak1. It was previously
observed that the V protein of MV co-purified with STAT1 and
that MV infection suppressed the phosphorylation of Jak1 and
STAT1 (Palosaari et al., 2003; Yokota et al., 2003). A direct
interaction was recently demonstrated between the V protein of
MV and both Jak1 and STAT1, and the tyrosine at amino acid
110 was necessary for interaction with STAT1, but not Jak1
(Caignard et al., 2007). Devaux et al. (2007) reported that a
tyrosine at amino acid 110 was required for the P protein of MV
to inhibit STAT1 phosphorylation and nuclear translocation, and
described a putative hexapeptide, Y(Y/H)VYDH, beginning at
position 110 that is conserved among six morbilliviruses. For
Nipah virus, amino acids 100 to 150 in the common amino-
terminal domain of the P, V, and W proteins were sufficient for
their STAT-1-binding activity (Rodriguez and Horvath, 2004;
Shaw et al., 2004). Preliminary observations identified a short
sequence, DVVYHD, in this region that resembles the hexa-
peptide observed in genus Morbillivirus, and is conserved
between Nipah and Hendra viruses, both members of the genus
Henipavirus. These data suggest a common mechanism for V
protein antagonism of the IFN-α/β and IFN-γ signaling path-
ways, as well as continuity in this function across genera.
Previous studies have investigated the sensitivity of atte-
nuated and wild-type strains of MV to IFN treatment. Naniche
et al. (2000) showed that wild-type strains of MV were more
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additional studies showed that wild-type strains were less sen-
sitive than attenuated strains to IFN-α treatment (Obojes et al.,
2005; Ohno et al., 2004). Wild-type and vaccine-like strains of
MV were equally sensitive to the presence of IFN-γ (Obojes
et al., 2005). In our study, there was no association between the
IFN-sensitivity of MV and its designation as a wild-type or
attenuated strain. The discrepancies between our result and the
results of previous studies could be due to the use of different
cell types, the addition of IFN at different times relative to
infection, or the number and choice of strains studied. Taken
together, these studies indicate that wild-type and attenuated
strains of MV cannot be distinguished based on their sensitivity
to IFN treatment.
A surprising finding was that the vaccine strains were highly
variable in their sensitivity to IFN treatment. Although all MV
vaccine strains in use have been proven safe and efficacious, some
biologic differences between strains have been reported.
Immunization with EZ induced higher rates of seroconversion
compared to the Schwarz vaccine strain at equivalent titers (Cutts
et al., 1995), and it has been suggested that EZ is more immu-
nogenic than other Edmonston-derived MV vaccine strains
(Sabin et al., 1984, 1983). It is possible that the EZ strain more
effectively inhibits innate defense mechanisms than some of the
other MV vaccines. Our study supports this conclusion because
EZ was less sensitive to IFN treatment than Moraten. Another
interesting finding was that CAM-70 was less sensitive to IFN-β
than all other attenuated strains. CAM-70 was the only non-
Edmonston-derived attenuated strain in this study and it has been
shown to be the most genetically divergent, especially with re-
gards to the P gene, of all genotype Avaccine viruses (Rota et al.,
1994; Santos et al., 2003).
Although no association between attenuation status and IFN-
sensitivity was detected, the level of sensitivity of a majority of
the strains (EdTag, EZ, Indiana, and D87-V/S) correlated to the
ability of its V protein to inhibit IFN signaling. Most notably,
EdTag was extremely sensitive to the presence of IFN-α/β and
IFN-γ and its V protein was impaired in its ability to inhibit
signaling. No such correlation was seen for the Moraten and
CAM-70 strains. This inconsistency could be attributed to the
involvement of other viral proteins in the inhibition of IFN, such
as the P protein (Devaux et al., 2007). Since the IFN-antagonist
activity of the V protein can be regulated by a substitution at
amino acid 110 in its shared domain with the P protein, it is
difficult to separate the functions of these two proteins in the
context of a viral infection. Additionally, the attenuation of
these strains could have resulted in other changes leading to
altered viral replication in the presence of IFN. For example, the
predicted amino acid sequences of the V proteins of Moraten
and EZ are identical. Therefore, other viral factors may attribute
to the different IFN-sensitivity of these viruses. Another expla-
nation could be that the time course of P, V and C protein
production varies among different strains of MV.
In the context of viral infection, evasion of the IFN response
is complicated and may involve interplay between multiple viral
and host proteins as well as the need to block IFN induction in
addition to signaling. There is increasing evidence that the Cand V proteins of paramyxoviruses may also inhibit IFN induc-
tion (Andrejeva et al., 2004; Childs et al., 2007; He et al., 2002;
Kiyotani et al., 2007; Komatsu et al., 2007; Nakatsu et al., 2006;
Poole et al., 2002; Strahle et al., 2007). This report furthers our
understanding of how the C and V proteins of MV function to
inhibit IFN signaling. Studies regarding the other functions of
the C and V proteins will be necessary to fully understand the
contribution of these proteins to viral pathogenesis.
Materials and methods
Cells and viruses
Vero cells were maintained in Eagle's Minimum Essential
Medium (EMEM; Mediatech) supplemented with 10% fetal
bovine serum (FBS; Atlas Biologicals). Vero/hSLAM cells (Ono
et al., 2001) which stably express the human signaling lym-
phocyte activation molecule (SLAM), a receptor of MV infection
(Tatsuo et al., 2000), were maintained in EMEM supplemented
with 10% FBS and 400 μg/mL G418 sulfate (Mediatech).
The Kitasato submaster seed of the CAM-70 strain (Isomura
et al., 1986; Okuno et al., 1971; Sangkawibha et al., 1971; Ueda
et al., 1970) was provided by I. Yoshida, Kanonji Institute,
Osaka, Japan. The Moraten strain (Enders and Peebles, 1954)
was obtained from Merck, Sharp and Dohme. The Edmonston–
Zagreb strain (EZ) (Bennett et al., 1999; Ikic et al., 1972) was
provided by D. Ikic, Institute of Immunology, Zagreb, Croatia.
The EdTag virus, which was recovered using reverse genetics
from cloned cDNA based on the sequence of the Edmonston B
strain of MV (Radecke and Billeter, 1996; Schneider et al.,
1997), was provided by M. Billeter, University of Zürich,
Zürich, Switzerland. All attenuated virus strains were plaque
purified and propagated in Vero cells. The Indiana strain (MVi/
Indiana.USA/22.05) is a wild-type virus of genotype D4 (World
Health Organization, 2006) that was isolated in 2000 from a
human clinical isolate and has been passaged four times on
Vero/hSLAM cells. The Davis87 strain is a wild-type virus of
genotype D3 that causes disease in rhesus macaques and was
isolated on rhesus PBMCs after an outbreak at a primate facility
(McChesney et al., 1997). The original Davis87 stock was
provided by M. McChesney, University of California, Davis,
California and has been passaged nine times in Vero/hSLAM
cells, resulting in a stock that is referred to as D87-V/S. The
D87-V/S virus was sequenced to confirm the absence of nu-
cleotide changes compared to the parental strain (Bankamp
et al., in press).
IFN sensitivity assay
IFN sensitivity tests were performed as previously described
(Ohno et al., 2004). Briefly, Vero/hSLAMcells were infectedwith
various strains of MV at a multiplicity of infection (m.o.i.) of
0.001. 1 h post-infection, inoculum was removed and cells were
treated with either 1000U/mL rhIFN-β (Biosource International),
1000 U/mL rhIFN-γ (R&D Systems), or left untreated in 5 mL
EMEM/G418 and 2% FBS. After 48 h, virus was harvested and
titrated on Vero/hSLAM cells.
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decrease in viral titer. A decrease in viral titer of 1- to 10-fold
was defined as “minimally sensitive,” a decrease of 10- to 100-
fold was defined as “intermediately sensitive,” and decrease of
100-fold and beyond was defined as “extremely sensitive.”
Derivation of plasmids
Total RNAwas extracted from MV-infected Vero cells using
Trizol® Reagent (Invitrogen) according to the manufacturer's
instructions. RT-PCR with gene-specific primers was performed
using SuperScript™ One-Step RT-PCR System with Platinum®
Taq DNA Polymerase (Invitrogen) to obtain cDNAs encoding
the C and V genes. The primers used to amplify the C gene were
as previously described (Shaffer et al., 2003), and were designed
to exclude the first 12 nucleotides of the P ORF. V cDNAs were
identified by screening cDNA obtained using previously
described primers (Bankamp et al., 2002) that amplified the
entire P ORF and silenced the C ORF for the presence of a non-
templated guanosine insertion at the RNA editing site. The C and
Vamplicons were digested with EcoRI and XhoI and ligated into
the plasmid vector, pCAGGS, to which a linker containing
EcoRI and XhoI recognition sites was added. The mammalian
expression vector, pCAGGS, has been previously described
(Niwa et al., 1991), and was provided by C. Basler, Mount Sinai
School of Medicine, New York, New York.
Site-directed mutagenesis was performed by amplifying the
coding region from the plasmid containing MV V by using a
three-step PCR reaction with the primers described above and
primers containing the desired mutation (underlined), CAMF (5′-
GCACTGGGTTACAGTGTTATTATG TTTATGATCACA
GCG G-3′), CAMR (5′-CCG CTG TGA TCATAA ACA TAA
TAA CAC TGTAGC CCA GTG C-3′), EdTagF (5′-GCA CTG
GGC TAC AGT GTTATTATG TTTATG ATC ACA GCG G-
3′), and EdTagR (5′-CCG CTG TGATCATAA ACATAATAA
CAC TGTAGC CCA GTG C-3′). The mutated amplicons were
digestedwith EcoRI and XhoI and ligated back into the pCAGGS
vector. All pCAGGS-C and pCAGGS-V clones were sequenced
using ABI PRISM Dye Terminator Reaction Kit and the ABI
3100 and 3130xL Genetic Analyzer machines (Perkin Elmer-
Applied Biosystems) according to the manufacturer's instruc-
tions. Sequence data were analyzed with the Sequencher™DNA
sequencing program (Gene Codes Corporation), and confirmed
by comparison to the published sequence for each strain.
A pGEM-4 expression vector encoding the four C proteins of
Sendai virus was provided by S. Moyer, University of Florida
College of Medicine, Gainesville, Florida. The C gene of Sendai
virus was excised from this vector using MluI and XhoI and
cloned into the pCAGGS vector.
The pISRE and pGAS plasmids were gifts from R.E. Randall,
North Haugh University of St. Andrews, Fife, Scotland. pISRE
encodes the firefly luciferase gene following four tandem repeats
of the IFN-stimulated response element (ISRE) from the IFN
inducible gene 9-27 (Didcock et al., 1999; Garcin et al., 1999;
King and Goodbourn, 1998). pGAS contains the minimal thy-
midine kinase promoter and two tandem repeats of the IFN-γ
activating sequence (GAS) from the IRF-1 gene (King andGoodbourn, 1998). The pRL-TK plasmid (Promega) encodes the
renilla luciferase gene constitutively expressed from a thymidine
kinase promoter and was used as a transfection control.
Expression of C and V proteins
Vero cells were cultured to 70% confluency in 6-well plates
and transfected with plasmids expressing C, V, or V mutants in
Opti-MEM medium (Life Technologies) and TransIT®-LT1
(Mirus Bio) following the manufacturer's recommendation.
pCAGGS without a coding sequence was used as a negative
control for protein expression. 48 h post-transfection, cells were
starved for 1 h in methionine-free medium (ICN), labeled for 2 h
with 35S-methionine, and then lysed in RIPA buffer (1% sodium
deoxycholate, 1% Triton X-100, 0.2% SDS, 150 mM NaCl, and
50 mM Tris–HCl at pH 7.5). Aliquots of cell extracts were
precleared with normal rabbit serum and then incubated with
C-specific or P/V-specific rabbit antiserum overnight on a
rotator at 4 °C. Complexes were precipitated with GammaBind
G-Sepharose (Amersham Pharmacia Biotech) and washed with
RIPA buffer. Samples were boiled for 5 min in SDS-PAGE
sample buffer and separated on an 8-16% gradient SDS-PAGE
gel (Bio-Rad Laboratories). After electrophoresis, bands were
visualized by autoradiography.
IFN-responsive reporter gene assay
Vero cells were cultured to 70% confluency in 24-well plates
and transfected with Opti-MEM medium and TransIT®-LT1
(Mirus Bio) following the manufacturer's recommendation.
pISRE or pGAS and pRL-tk were co-transfected with various
doses of pCAGGS-C or pCAGGS-V plasmid DNA. pCAGGS
without a coding sequence was used to make up the difference in
total plasmid concentration, and also constituted a negative
control for inhibition of IFN-responsive gene expression. A
plasmid encoding the C proteins of Sendai virus, which are
known to inhibit both IFN-α/β and IFN-γ signaling (Garcin et al.,
2002; Kato et al., 2001; Saito et al., 2002), was used as a positive
control for inhibition of IFN-responsive gene expression. 48 h
post-transfection, cells were stimulated with 100 U rhIFN-β or
1000 U rhIFN-γ for 6 h. pCAGGS that was unstimulated con-
stituted a negative control for IFN signaling, and was used to
demonstrate background levels of firefly luciferase luminescence.
Cell lysates were harvested for detection of luciferase activity
using the Dual Reporter Luciferase System (Promega) according
to the manufacturer's protocol. Chemiluminescence was quan-
tified on a Luminoskan Ascent FL microplate luminometer
(Thermo Electron). To control for transfection efficiency, data
were expressed as a ratio of firefly to renilla luciferase lumi-
nescence and taken as a percentage of luminescence obtained
using IFN-stimulated, empty pCAGGS vector.
Statistical analysis
For two group comparisons, a two-tailed Student's t-test
was used, and a value of pb0.05 was considered statistically
significant.
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